Literature DB >> 11038162

Human serum paraoxonase (PON1) isozymes Q and R hydrolyze lactones and cyclic carbonate esters.

S Billecke1, D Draganov, R Counsell, P Stetson, C Watson, C Hsu, B N La Du.   

Abstract

It is well established that human serum paraoxonase (PON1) catalyzes the hydrolysis of organophosphate insecticides and nerve agents, as well as that of a number of aromatic carboxylic acid esters. Our laboratory has recently found a new class of PON1 substrates that includes at least 30 lactones and cyclic carbonate esters. The lactone substrates vary in their ring size from 4 to 7 atoms. Substituents on the ring carbons may enhance or reduce the rate of lactone hydrolysis. An appreciable degree of stereospecificity exists with some activities differing up to 9-fold between enantiomers (i.e., S-alpha-hydroxy-gamma-butyrolactone is hydrolyzed 5 to 9 times faster than the R form). Thiolactones are hydrolyzed less efficiently, and some lactams are potent inhibitors. Four lactone-containing drugs-spironolactone, mevastatin, simvastatin, and lovastatin-have been identified as substrates for PON1. All lactone substrates are hydrolyzed by both the Q and R isozymes of human serum PON1. However, some lactone substrates are hydrolyzed faster by the Q than R isozyme, whereas others show a reverse preference. Moreover, these new substrates include homogentisic acid lactone, mevalonic acid lactone, homocysteine thiolactone, and gamma-hydroxybutyric acid lactone-all lactone forms of endogenous compounds. It is reasonable to expect that further investigations may uncover PON1 lactone substrates that are, themselves, endogenous compounds. In this article we characterize the basic enzymatic properties of PON1's newly identified hydrolytic activities with lactone and cyclic carbonate ester substrates and compare these properties with those of representative arylesters and organophosphates.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11038162

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  70 in total

1.  Directed evolution of mammalian paraoxonases PON1 and PON3 for bacterial expression and catalytic specialization.

Authors:  Amir Aharoni; Leonid Gaidukov; Shai Yagur; Lilly Toker; Israel Silman; Dan S Tawfik
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-26       Impact factor: 11.205

2.  High chlorpyrifos resistance in Culex pipiens mosquitoes: strong synergy between resistance genes.

Authors:  H Alout; P Labbé; A Berthomieu; P Makoundou; P Fort; N Pasteur; M Weill
Journal:  Heredity (Edinb)       Date:  2015-10-14       Impact factor: 3.821

Review 3.  Paraoxonases as protective agents against N-acyl homoserine lactone - producing pathogenic microorganisms.

Authors:  Bogdan Nicolae Manolescu
Journal:  Maedica (Bucur)       Date:  2013-03

Review 4.  Pharmacological and dietary modulators of paraoxonase 1 (PON1) activity and expression: the hunt goes on.

Authors:  Lucio G Costa; Gennaro Giordano; Clement E Furlong
Journal:  Biochem Pharmacol       Date:  2010-11-18       Impact factor: 5.858

Review 5.  Quorum-quenching microbial infections: mechanisms and implications.

Authors:  Y-h Dong; L-y Wang; L-H Zhang
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2007-07-29       Impact factor: 6.237

Review 6.  Quorum sensing: fact, fiction, and everything in between.

Authors:  Yevgeniy Turovskiy; Dimitri Kashtanov; Boris Paskhover; Michael L Chikindas
Journal:  Adv Appl Microbiol       Date:  2007       Impact factor: 5.086

7.  Characterization of human paraoxonase 1 variants suggest that His residues at 115 and 134 positions are not always needed for the lactonase/arylesterase activities of the enzyme.

Authors:  Priyanka Bajaj; Rajan K Tripathy; Geetika Aggarwal; Abhay H Pande
Journal:  Protein Sci       Date:  2013-10-26       Impact factor: 6.725

8.  Paraoxonase-1 and clopidogrel efficacy.

Authors:  Patrick M Dansette; Julien Rosi; Gildas Bertho; Daniel Mansuy
Journal:  Nat Med       Date:  2011-09-07       Impact factor: 53.440

9.  In vivo administration of BL-3050: highly stable engineered PON1-HDL complexes.

Authors:  Leonid Gaidukov; Dganit Bar; Shiri Yacobson; Esmira Naftali; Olga Kaufman; Rinat Tabakman; Dan S Tawfik; Etgar Levy-Nissenbaum
Journal:  BMC Clin Pharmacol       Date:  2009-11-17

10.  A common mutation in paraoxonase-2 results in impaired lactonase activity.

Authors:  David A Stoltz; Egon A Ozer; Thomas J Recker; Miriam Estin; Xia Yang; Diana M Shih; Aldons J Lusis; Joseph Zabner
Journal:  J Biol Chem       Date:  2009-12-18       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.